In this article, we discuss 11 Best Falling Stocks to Buy According to Analysts.

Over the past two years, bulls have been in control, pushing US markets to new heights with each pullback. Major indices rallied to record highs as artificial intelligence emerged as a key investment theme, especially in the technology sector. Stocks also rallied amid expectations that the US Federal Reserve will cut interest rates on inflationary pressures subsiding significantly. The rally to record highs saw valuations get out of hand beyond historical norms.

A change of administration and policies in the US was always going to be the catalyst to sway investors to exit risky bets amid the premium valuations. Donald Trump’s taking over, waging a trade war against allies, and imposing stringent tariffs on imports into the US is the latest headwind that is sending US equity markets lower.

The S&P 500 is already down by about 6%, and the tech-heavy NASDAQ is down by about 8%. The pullbacks come on growing concerns that the tariff war fuelled by Trump could plunge the global economy into recession. Similarly, there are growing fears that the US Federal Reserve will refrain from cutting interest rates as inflationary pressures show signs of edging higher.

Consequently, the US equity market remains on edge, with stocks exposed to the tariff war pulling back by double-digit percentage points. The uncertainty around President Trump’s tariffs and policies is sure to heighten volatility in the markets, as was the case in his first term.

Trump’s announcement of tariffs on Chinese imports in 2018 and 2019 caused stocks to perform poorly, according to data from economists at the Federal Reserve Bank of New York. Fast forward, we are seeing a repeat of similar performance in 2025, but on a larger scale.

Nevertheless, a falling stock market will always present unique investment opportunities for investors with a high-risk tolerance. As prices come down, opportunities to invest in stocks trading at highly discounted valuations are increasingly cropping up.

″‘Buying the dip’ depends upon your timeframe,” says Richard Smith, CEO of investing tool RiskSmith. “If you can keep your money in the markets for at least a couple of years, this is a good dip to buy. You’ll likely be disappointed if you’re banking on the market reversing [soon] and heading back up to new highs.”

Although it’s unclear if the stock sell-off will steepen in the weeks to come, there are exceptionally safe, historically inexpensive, time-tested stocks worth buying on the dip. In line with Warren Buffett’s strategy of pursuing opportunities when there is a blood bath, the best stocks in a shaky market will always be those with a rare combination of quality and healthy potential for growth.

Our Methodology

To curate the list of the 11 best-falling stocks to buy according to analysts, we used the Finviz stock screener. We defined falling stocks as those trading within 0% to 10% of their 52-week lows. Using the Finviz stock screener, we got an aggregated list of stocks that fit our criteria. Next, we ranked these stocks in ascending order based on analysts’ upside potential (as of May 2). We have also mentioned the hedge fund sentiment around each stock, as of Q4 2024.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

11 Best-Falling Stocks to Buy According to Analysts

11. Healthpeak Properties, Inc. (NYSE:DOC)

52 Week Range: $17.33 – $23.26

Current Share Price: $17.78

Analysts Upside Potential as of May 2: 31.73%

Number of hedge fund holders: 37

Healthpeak Properties, Inc. (NYSE:DOC) is a healthcare real estate investment trust (REIT). It owns, operates, and develops real estate properties primarily for healthcare-tailored facilities. While the stock has pulled back significantly to the brink of its 52-week low, it is one of the best-falling stocks to buy, according to analysts, for gaining exposure in the real estate sector.

Likewise, analysts at Baird maintained an Outperform rating on Healthpeak Properties, Inc. (NYSE:DOC) even after cutting the price target to $22 from $24 on April 29. The bullish stance stems from the company offering an enticing 6.49% dividend yield, affirming its commitment to shareholder value. In addition, it delivered solid Q1 2025 results that beat analysts’ expectations. Earnings per share totaled $0.06 against $0.0519 expected. Revenue totaled $702.89 million against $683.39 million expected.

Healthpeak Properties, Inc. (NYSE:DOC) affirmed its ability to generate stable income and return value to shareholders in the long run by executing 1.2 million square feet of new and renewal leases. As of the end of Q1, its medical leases stood at 973,000 square feet and lab leases at 276,000 square feet. The company has also entered into a long-term partnership with Hines for a multifamily component in Massachusetts, further strengthening its footprint.

10. Avantor, Inc. (NYSE:AVTR)

52 Week Range: $12.20 – $28

Current Share Price: $12.96

Analysts Upside Potential as of May 2: 32.64%

Number of hedge fund holders: 39

Avantor, Inc. (NYSE:AVTR) is a medical instruments and supplies company that provides mission-critical products and services to customers in biopharma, healthcare, education, and government sectors. Its stock has been under pressure, going by the 38% year-to-date slide. On April 28, RBC Capital reiterated a Buy rating on the stock but cut the price target to $20.

On April 25, Avantor, Inc. (NYSE:AVTR) delivered mixed first-quarter 2025 results. While adjusted earnings per share came in at 23 cents better than the 22 cents a share delivered the same quarter last year, revenue fell 5.9% year-over-year to $1.58 billion. The sales slump was fueled by an 8% drop in the Laboratory Solutions segment, which was impacted by lower demand.

The stock remains under pressure on the confirmation that CEO Michael Stubblefield is stepping down and a cut to the guidance. The company expects organic revenue to range between 1% and -1%, down from the previous guidance of 1% to 3%. It also expects EBITDA margin to range between 17.5% and 18.5%, down from an initial guidance of 18% to 19%. Avantor, Inc. (NYSE:AVTR) has reviewed its full-year outlook to reflect funding and policy-related headwinds. Nevertheless, the company has also moved to strengthen its Lab solution segment. It also plans to cut operational costs by $400 million by 2027.

9. Thermo Fisher Scientific Inc. (NYSE:TMO)

52 Week Range: $409.85 – $627.88

Current Share Price: $419.89

Analysts Upside Potential as of May 2: 34.07%

Number of hedge fund holders: 100

Thermo Fisher Scientific Inc. (NYSE:TMO) is a diagnostics and research company that provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. It provides reagents, instruments, and consumables for biological and medical research. Its stock has pulled back significantly after a 17% year-to-date slide, leaving it close to its 52-week low.

Amid the slump, Thermo Fisher Scientific Inc. (NYSE:TMO) is still one of the best-falling stocks to buy according to analysts. Despite cutting its price target to $470 from $620, analysts at Argus Research maintain a Buy rating on the stock. The Buy stance comes on the backdrop of Thermo Fisher Scientific unveiling an enhanced technology platform and a new CHO K-1 cell line. The two promise to reduce the investigational New Drug filing timelines from 13 months to nine. The new system is also poised to enable a new era of biologics drug development.

In addition, Thermo Fisher Scientific Inc. (NYSE:TMO) has inked a strategic partnership with RoosterBio, a leading supplier of adult human mesenchyme stem/stromal cells (hMSCs). The two are joining forces to accelerate the development of new potentially lifesaving cell and exosome therapies as they seek to tap growth opportunities in treating degenerative diseases.

8. FedEx Corporation (NYSE:FDX)

52 Week Range: $194.30 – $313.84

Current Share Price: $210.06

Analysts Upside Potential as of May 2: 34.80%

Number of hedge fund holders: 66

FedEx Corporation (NYSE:FDX), formerly Federal Express and FDX Corporation, is a leading American multinational specializing in transportation, e-commerce, and business services, headquartered in Memphis, Tennessee. FedEx Corporation (NYSE:FDX) holds a Moderate Buy rating from 19 analysts, with 14 buy, 3 hold, and 2 sell ratings. The 12-month average price target is $283.16, ranging from $200.00 to $365.00, reflecting a 34.80% increase from its current price of $210.06.

FedEx Corporation (NYSE:FDX) reported Q3 FY 2025 earnings of $4.51 per share, missing the $4.56 estimate. Revenue rose 2% YoY to $22.2 billion, with adjusted earnings of $1.09 billion, up from $970 million ($3.86 per share) a year prior. Despite the growth, results fell short of expectations. FedEx lowered its full-year EPS forecast to $15.15-$15.75 from $16.45-$17.45 and expects revenue to be flat or slightly lower, citing economic headwinds and cost pressures.

Raj Subramaniam, FedEx Corp. president and CEO, acknowledged the company’s improved profitability despite challenges, stating, “The FedEx team delivered improved profitability, while navigating a very challenging operating environment, including a compressed Peak season and severe weather events.” He praised the team’s efforts, adding, “I am proud of the team for executing on our transformation efforts while strengthening our value proposition and improving the customer experience.” Looking ahead, he emphasized FedEx’s commitment to customer support, saying, “We remain focused on supporting our customers amid the shifting macroeconomic environment.”

7. Becton, Dickinson and Company (NYSE:BDX)

52 Week Range: $169.52 – $251.99

Current Share Price: $169.54

Analysts Upside Potential as of May 2: 37.43%

Number of hedge fund holders: 56

Becton, Dickinson, and Company (NYSE:BDX) is a medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. Its products are used to improve drug delivery, enhance diagnostics, and advance medical discovery research. While the stock has slid 8% year-to-date, Piper Sandler analyst Jason Bednar insists it is a Buy with a $260 price target.

The bullish stance stems from the leading force in the Healthcare Equipment & Supplies industry delivering strong Q2 2025 results. Becton, Dickinson, and Company (NYSE:BDX) delivered a 4.5% revenue growth to $5.3 billion as earnings per share totaled $3.35. Concerned by the impact of tariffs, Becton Dickinson and Company says it expects its full-year revenue to range between $21.8 billion and $21.9 billion with diluted EPS of between $14.06 and $14.34.

In addition, Becton, Dickinson, and Company (NYSE:BDX) is planning a $2.5 billion investment in the US as it looks to enhance its manufacturing capacity in response to the trade tariffs. It also plans to strengthen its market leadership and improve its product portfolio through new launches and FDA clearance.

6. The AES Corporation (NYSE:AES)

52 Week Range: $9.57 – $22.21

Current Share Price: $10.23

Analysts Upside Potential as of May 2: 40.69%

Number of hedge fund holders: 53

The AES Corporation (NYSE:AES) is a utility company that develops, constructs and operates power generation and distribution facilities. It is one of the best falling stocks to buy despite going down by about 21% year to date. JPMorgan analyst Richard Sunderland has already reiterated a Buy rating on the stock but cut the price target to $14. The bullish stance comes from AES Corp demonstrating resilience to tariffs and economic policies.

The company has reaffirmed its 2025 guidance and long-term growth rates despite plunging into a Q1 2025 net loss of $73 million compared to a net income of $278 million delivered last year. The AES Corporation (NYSE:AES) expects its full-year adjusted EBITDA to range between $2.65 billion and $2.85 billion at the back of an annualized growth target of between 5% and 7% through 2027.

The robust growth should come as The AES Corporation (NYSE:AES) increasingly executes its clean energy transition with a significant renewable backlog of 11.7 GW. It has also completed 643 MW of energy storage and solar projects. Its growth pipeline has also received a significant boost with the signing of PPAs for 443 MW of solar and energy storage capacity. Additionally, AES has quashed tariff impact concerns given that its major equipment are either on-site or contracted for domestic production.

5. Nike, Inc. (NYSE:NKE)

52 Week Range: $52.28 – $98.04

Current Share Price: $56.76

Analysts Upside Potential as of May 2: 40.69%

Number of hedge fund holders: 73

Nike, Inc. (NYSE:NKE) is a global footwear and apparel company. It designs, develops, markets, and sells athletic footwear, apparel, equipment, accessories, and services. According to analysts, the stock has pulled back significantly, making it a worthy candidate for the best-falling stocks to buy. On April 25, BofA analyst Lorraine Hutchinson cut Nike’s (NKE) price target to $80 from $90, maintaining a Buy rating. The firm cited market multiple compression for the adjustment but believes tariffs are manageable and the weakening U.S. brand demand in China is already priced in.

Nike, Inc.’s (NYSE:NKE) 23% year-to-date slide comes amid concerns that it is highly exposed to the tariff war. The apparel maker produces at least 28% of its Nike Brand goods in Vietnam, 16% in China, and 15% in Cambodia. With all three countries being hit hard by Trump tariffs, its profit margins could be pressured.

Nike, Inc. (NYSE:NKE) delivered mixed third-quarter fiscal 2025 results whereby revenues fell 9% to $11.3 billion as gross margin fell 330 basis points to 41.5%. Faced with a challenging macro environment amid the trade war, the company is turning to new product innovation, focusing on reigniting brand momentum to drive sales among athletes. It has also reiterated its commitment to returning value to shareholders, having returned $1.1 billion through buybacks and share repurchases in Q3.

4. UnitedHealth Group Incorporated (NYSE:UNH)

52 Week Range: $399.86 – $630.73

Current Share Price: $400.68

Analysts Upside Potential as of May 2: 41.01%

Number of hedge fund holders: 150

UnitedHealth Group Incorporated (NYSE:UNH) is a healthcare company that offers consumer-oriented health benefit plans and services. It also provides care delivery, wellness and consumer engagement, and health financial services to patients. While its stock has experienced a notable downturn, going by the 18% year-to-date slide, it is still one of the best-falling stocks to buy, according to analysts.

Research firm Baird has already reiterated a Buy rating on UnitedHealth Group Incorporated (NYSE:UNH) after the significant pullback but cut the price target to $510 from $640. The price cut comes on the company experiencing its steepest 1-day drop of 22% in more than a century as investors reacted to higher Medicare costs. Amid the escalating costs, UnitedHealth Group was still able to deliver $6.3 billion in profit in Q1 2025 due to growth in its Medicare Advantage line of business.

Additionally, the stock stands out owing to its exceptional track record in paying and growing dividends over the past 14 years. Its 1.4% dividend yield is almost equal to that of the S&P 500 average. In addition, the UnitedHealth Group Incorporated (NYSE:UNH) often turns to acquisitions to grow its business. It has already acquired the home health business Luck Group and is in the process of closing a $3.3 billion deal for Amedisys to strengthen its home health services further.

3. Schlumberger Limited (NYSE:SLB)

52 Week Range: $31.11 – $50.94

Current Share Price: $33.74

Analysts Upside Potential as of May 2: 44.36%

Number of hedge fund holders: 80

Schlumberger Limited (NYSE:SLB) focuses on energy innovation, particularly in the oil and gas sector. The company has been under pressure on oil prices tanking below the $70 a barrel level. Likewise, the stock has slid by about 13% year-to-date. Amid the slump, it is one of the best falling stocks to buy, according to analysts, given the role it plays in the multi-billion energy sector.

Analysts at Stifel Research firm have already reiterated a Buy rating on Schlumberger Limited (NYSE:SLB) with a steady price target of $31.95. The bullish stance comes on SLB raising its quarterly dividend by 3.6% and increasing its share buyback authorization to at least $4 billion, affirming strong cash flow. Nevertheless, the oil field services company has warned of a potential downturn in oil producers’ spending due to the impact of tariffs.

The remarks come on Q1 2025 revenues dropping 3% year-over-year to $8.49 billion. However, robust growth in North America, going by an 8% year-over-year revenue increase due to strong data center infrastructure growth, is helping offset the losses. Schlumberger Limited (NYSE:SLB) is additionally concentrating on minimizing costs and aligning its resources with expected activity levels in the forthcoming quarters.

2. Petroleo Brasileiro (NYSE:PBR)

52 Week Range: $11.03 – $17.41

Current Share Price: $11.35

Analysts Upside Potential as of May 2: 48.27%

Number of Hedge Fund Holders: 31

Petroleo Brasileiro (NYSE:PBR) is a Brazilian government-controlled energy company engaged in oil and gas exploration, production, refining, and marketing. It operates through three segments: Exploration & Production, Refining & Marketing, and Gas & Power, with a focus on efficiency and low carbon emissions. The stock has declined 13.67% year to date, reflecting ongoing market challenges.

On April 29, Petroleo Brasileiro (NYSE:PBR) reported Q1 2025 production of 2.77 million barrels of oil equivalent per day (boed), down 0.2% YoY, with Brazilian oil output falling 1% YoY to 2.21 million barrels per day (bpd). The FPSO Almirante Tamandare began operations in February at the Buzios field, supporting sustainable production growth. Sales of oil, gas, and derivatives reached 2.86 million boed, a 1.9% YoY drop, while exports declined 10.4% to 760,000 bpd. However, oil exports to Asia (excluding China) rose from 10% to 33%. Petrobras also signed a 6-million-barrel annual export deal with India’s Bharat Petroleum Corporation, starting in 2025.

Petroleo Brasileiro (NYSE:PBR) holds a Strong Buy rating from 6 analysts, with 5 buy, 1 hold, and 0 sell ratings. The 12-month average price target is $16.74, ranging from $15.00 to $19.00, reflecting a 47.49% upside from its $11.35 current price.

1. Freshpet, Inc. (NASDAQ:FRPT)

52 Week Range: $71.19 – $164.07

Current Share Price: $72.72

Analysts Upside Potential as of May 2: 63.30%

Number of hedge fund holders: 40

Freshpet, Inc. (NASDAQ:FRPT) is a company that manufactures, markets and distributes fresh, refrigerated pet food for dogs and cats. It focuses on fresh, natural ingredients and offers a variety of products, including meals and treats, all while maintaining freshness through refrigerated storage. Despite delivering solid financial results, the stock has shed about 49% in market value year to date.

Its net sales increased 27.2% in 2024 to $975.2 million as Freshpet, Inc. (NASDAQ:FRPT) jumped to profitability with a net income of $46.9 million compared to a net loss of $33.6 million in 2023. Likewise, gross margins improved to 40.6% from 32.7% in 2023. Management has already reiterated they remain focused on delivering disciplined, consistent growth and outsized profitability improvements in 2025.

Likewise, Benchmark Co. analyst Todd Brooks reiterated a Buy rating on the stock on April 20 with a $140 price target. The bullish stance comes on growing optimism that Freshpet, Inc. (NASDAQ:FRPT) will continue to dominate the fresh dog food segment.

While we acknowledge the potential of Freshpet, Inc. (NASDAQ:FRPT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than FRPT but that trades at less than 5 times its earnings check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.